Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leridistim vs Filgrastim in Older AML Patients Receiving Chemotherapy
NCT00004215Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 1999
- Primary completion
- Aug 2000
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of leridistim in neutropenia and Thrombocytopenia (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose at Day 42 and Duration of Grade IV Neutropenia. Started Aug 1999; status: completed.
02
Drugs
leridistim
03
Conditions
neutropeniaThrombocytopenia
Beyond the preview
Go deeper on NCT00004215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004215.